Antibiotics 2020, 9, 603; doi:10.3390/antibiotics9090603 www.mdpi.com/journal/antibiotics

Article

Antibiogram, Prevalence of OXA Carbapenemase Encoding Genes, and RAPD-Genotyping of Multidrug-Resistant Acinetobacter baumannii Incriminated in Hidden Community-Acquired Infections

Waleed El-Kazzaz 1,*, Lobna Metwally 2,3, Reham Yahia 4, Najwa Al-Harbi 5, Ayat El-Taher 6 and Helal F. Hetta 7,8

1 Molecular Microbiology Lab., Botany Department, Faculty of Science, Suez Canal University, Ismailia 41522, Egypt
2 Microbiology and Immunology Department, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt; lobna.metwally@gmail.com
3 Department of Microbiology, College of Medicine, Taif University, Al-Taif 11099, Saudi Arabia
4 Basic Sciences Department, College of Science and Health Professions, King Saud Bin Abdul Aziz University for Health Sciences, Riyadh 11481, Saudi Arabia; yahyar@ksau-hs.edu.sa
5 Molecular Microbiology Lab., King Abdul Aziz University, Riyadh 11481, Saudi Arabia; nmaalharbi@kau.edu.sa
6 Botany Department, Faculty of Science, Suez Canal University, Ismailia 41522, Egypt; dr_ayateltaher@yahoo.com
7 Department of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt; helalheten@assu.edu.eg
8 Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 452221, USA

* Correspondence: waleid_elkazaz@science.suez.edu.eg; Tel.: +20-1066-633-457

Received: 13 July 2020; Accepted: 13 September 2020; Published: 15 September 2020

Abstract: Acinetobacter spp. has gained fame from their ability to resist difficult conditions and their constant development of antimicrobial resistance. This study aimed to investigate the prevalence, susceptibility testing, OXA carbapenemase-encoding genes, and RAPD-genotyping of multidrug resistant Acinetobacter baumannii incriminated in hidden community-acquired infections in Egypt. The antimicrobial susceptibility testing was assessed phenotypically using Kirby–Bauer disk diffusion method. Also, Modified-Hodge test (MHT) was carried out to detect the carbapenemases production. Multiplex-PCR was used to detect the carbapenemase-encoding genes. Furthermore, the genetic relationship among the isolated strains was investigated using RAPD fingerprinting. The bacteriological examination revealed that, out of 200 Gram-negative non-fermentative isolates, 44 (22%) were identified phenotypically and biochemically as Acinetobacter spp. and 23 (11.5%) were molecularly confirmed as A. baumannii. The retrieved A. baumannii strains were isolated from urine (69%), sputum (22%), and cerebrospinal fluid (csf) (9%). The isolated A. baumannii strains exhibited multidrug resistance and the production rates of carbapenemases were 56.5, 60.9, and 78.3% with meropenem, imipenem, and ertapenem disks, respectively. The blaOXA-24-like genes were the most predominant among the tested strains (65.2%), followed by blaOXA-23 (30.4%) and blaOXA-58 (17.4%), in addition, the examined strains are harbored IMP, VIM, and NDM genes with prevalence of 60.9, 43.5, and 13%, respectively, while KPC and GES genes were not detected. RAPD-PCR revealed that the examined strains are clustered into 11 different genotypes at ≥90% similarity. Briefly, to the best of our knowledge, this study is the first report concerning community-associated A. baumannii infections in Egypt. The high prevalence of hidden multidrug-resistant (MDR) and extensively drug-resistant (XDR) A. baumannii strains associated with non-hospitalized patients raises an alarm for healthcare authorities to set strict standards to control the spread of such pathogens with high rates of morbidity and mortality.
1. Introduction

The bacterium *A. baumannii* is a Gram-negative, aerobic, coccobacilli that is marked to the greatest extent as being significant to healthcare-associated pneumonia, blood, cerebrospinal fluid (csf), and urinary tract infections with high mortality and transmission rates and resistance to multiple classes of antimicrobials [1–3]. Although it is still considered rare, community-acquired *A. baumannii* infections have been reported primarily in equatorial and sub-equatorial regions [4,5]. Recently, an increase in community-acquired *Acinetobacter* infections is being reported [6–8]. Health settings-acquired *A. baumannii* showed higher resistance to antibacterial drugs than community-acquired pathogens, despite these mortality rates still being very high (64%) [5,9]. Misidentification of *Acinetobacter* spp. is a well-documented and accurate genus or species identification, which possess a challenge to microbiologists even with commercially-available kits like API 20NE and Vitek2 systems [10,11]. Occasionally, *Burkholderia pseudomallei* is misidentified as *Acinetobacter* spp. and *A. baumannii* as *Alcaligenes faecalis* [12,13]. Furthermore, the *A. calcoaceticus–A. baumannii* complex (i.e., genomospecies 1, 2, 3, and 13) share the majority of biochemical properties and are hard to discriminate based on conventional or commercial identification schemes, but they differ in clinical features [14,15].

The efflux pump, many types of β-lactam degrading enzymes, and small membrane porins are involved in the natural resistance of *A. baumannii* to a wide range of antimicrobials [16,17]. *Acinetobacter* spp. is naturally competent with high natural transformation rates that have an essential role in antibiotic resistance genes gaining and distribution [18,19]. For a long time, carbapenem was the best drug to control *A. baumannii* infections; however, the evolved carbapenem resistance due to carbapenemase limited its efficacy [20]. In *A. baumannii*, three types of β-lactamases have been reported as belonging to class A, B, and D of Ambler classification: class A including beta-lactamases inhibited by clavulanic acid such as TEM and SHV, and clavulanic acid insensitive enzymes like KPC and GES; class B including Metallo β-lactamases such as VIM, IMP, and NDM; and class D including oxacillinases [21–23]. Ambler class D β-lactamases are serine hydrolases that have the ability to hydrolyze oxacillin and are called oxacillinases (OXA). According to their protein primary structure, oxacillinases are grouped into several families or subclasses like *bla*\textsubscript{OXA-23}, *bla*\textsubscript{OXA-24}, *bla*\textsubscript{OXA-40}, *bla*\textsubscript{OXA-51}, *bla*\textsubscript{OXA-58}, *bla*\textsubscript{OXA-143}, and *bla*\textsubscript{OXA-23} families [24]. The persistence of OXA-51 gene family is found in *A. baumannii* strains and believed to be intrinsic to this genomic species, but recently, this was detected in another species, perhaps due to horizontal gene transfer [25,26]. *A. baumannii* can easily develop resistance to a new lactam ring containing antibiotics due to the presence of this variety of OXA enzymes. Therefore, *A. baumannii* has become one of the problematic pathogens with no or very few options for eradication [27]. Given the importance of class D carbapenemase, much research was conducted addressing their genetic variation, enzymatic characterization, prevalence, and extent of antibiotic resistance throughout the globe [28,29].

Although *A. baumannii* is not a frequent cause of community-acquired infections, the capacity to rapidly develop resistance mechanisms to antibiotics and the fulminant clinical presentation (with a mortality rate around 50%) makes this pathogen an important health problem in the community setting [30]. This study is concerned with the prevalence of the hidden and/or unidentified *A. baumannii* among community-acquired infections caused by Gram-negative, non-fermenting bacterial pathogens in Egypt. We aim to analyze their antimicrobial susceptibility pattern, evaluate the incidence rates of different types of carbapenemases, and check genetic relatedness between the isolates.
2. Results

2.1. Identification and Prevalence of the Hidden Community-Acquired A. baumannii

In this study, 200 (9.5%) Gram-negative, non-fermentative strains were selected among 2108 Gram-negative isolates identified at mega laboratories over the Suez Canal and Nile Delta regions in Egypt (1044 urine culture, 108 pus, 537 sputum, 322 blood, 23 cerebrospinal fluid, and 74 wound) from August 2017 to October 2018. The 200 strains were preliminary inoculated on MacConkey agar, blood agar, Acinetobacter agar, and CHROM agar media. Out of the 200 strains, 44 (22%) showed Acinetobacter spp. differential growth on agar media. Among the 44 strains, 29 (66%) were identified as A. baumannii by API 20 NE bacterial identification system. The intrinsic OXA-51 of A. baumannii was found in only 23 of the 44 strains. For the 23 isolates, the 16S-23S region of ribosomal RNA sequence analysis showed that 23 of the 44 strains having 99.89 to 100% identity to A. baumannii.

Table 1 elucidates the dissemination of Gram-negative non-fermentative isolates according to sample source and gender. The Gram-negative non-fermentative isolates were most prevalent in urine (38.5%), sputum (20.5%), wound (20%), blood (11%), pus (6%), and cerebrospinal fluid (csf) (4%). The most prevalent Gram-negative non-fermentative among the 200 isolates were Pseudomonas aeruginosa 156 (78%) followed by A. baumannii 23 (11.5%), A. lwoffii 7 (3.5%), A. calcoaceticus 6 (3%), Burkholderia cepacia 3 (1.5%), Stenotrophomonas maltophilia 3 (1.5%), and A. nosocomialis 2 (1%). P. aeruginosa was most prevalent in urine samples 57 (28.5%) followed by wound 35 (17.5%), sputum 31 (15.5%), blood 18 (9%), pus 10 (5%), and csf 5 (2.5%). The distribution of P. aeruginosa was higher in male patients (47%) than in female patients (31%) (Table 1).

Table 1. Distribution of Gram-negative non-fermentative isolates according to sample source and patient gender (n = 200).

| Strain                        | Sample Origin | Gender | Urine | Sputum | Pus | Blood | Wound | CSF * | Total n (%) | Collecting Lab. Identification % |
|-------------------------------|---------------|--------|-------|--------|-----|-------|-------|-------|-------------|----------------------------------|
| Pseudomonas aeruginosa        | Male          | 36     | 18    | 6      | 10  | 21    | 3     | 94    | 47 (100)    |                                  |
|                              | Female        | 21     | 13    | 4      | 8   | 14    | 2     | 62    | 31 (100)    |                                  |
|                              | Total         | 57     | 31    | 10     | 18  | 35    | 5     | 156   | 78 (100)    |                                  |
| Acinetobacter baumannii       | Male          | 0      | 1     | -      | -   | -     | 1     | 1     | 1 (100)     | unidentified                     |
|                              | Female        | 16     | 4     | -      | -   | -     | 1     | 21    | 10.5 (21)   | unidentified                     |
|                              | Total         | 16     | 5     | -      | -   | -     | 2     | 23    | 11.5 (23)   | unidentified                     |
| Acinetobacter lwoffii         | Male          | 2      | 3     | -      | 1   | -     | -     | 6     | 3 (100)     |                                  |
|                              | Female        | 1      | 0     | -      | 0   | -     | -     | 1     | 0.5 (1)     |                                  |
|                              | Total         | 3      | 3     | -      | 1   | -     | -     | 7     | 3.5 (7)     |                                  |
| Acinetobacter nosocomialis    | Male          | 0      | 1     | 1      | -   | 2     | -     | 4     | 2 (100)     |                                |
|                              | Female        | 1      | 0     | 0      | -   | 1     | -     | 2     | 1 (100)     |                                |
|                              | Total         | 1      | 1     | 1      | 3   | 6     | -     | 6     | 3 (100)     |                                |
| Acinetobacter calcoaceticus   | Male          | 0      | -     | 0      | -   | 1     | -     | 1     | 0.5 (1)     |                                |
|                              | Female        | 1      | -     | 0      | -   | 1     | -     | 2     | 1 (100)     |                                |
|                              | Total         | 1      | 1     | -      | 2   | 3     | -     | 3     | 1.5 (3)     |                                |
| Burkholderia cepacia          | Male          | 0      | -     | 0      | -   | 1     | -     | 1     | 0.5 (1)     |                                |
|                              | Female        | 1      | -     | 1      | -   | 1     | -     | 2     | 1 (100)     |                                |
|                              | Total         | 1      | 1     | -      | 2   | 3     | -     | 3     | 1.5 (3)     |                                |
| Stenotrophomonas maltophilia  | Male          | 0      | -     | 0      | -   | 1     | -     | 1     | 0.5 (1)     |                                |
|                              | Female        | 1      | -     | 0      | -   | 1     | -     | 2     | 1 (100)     |                                |
|                              | Total         | 1      | 1     | -      | 2   | 3     | -     | 3     | 1.5 (3)     |                                |
| Total                        | Male          | 38     | 23    | 8      | 12  | 24    | 5     | 110   | 55 (55)     |                                |
|                              | Female        | 39     | 18    | 4      | 10  | 16    | 3     | 90    | 45 (45)     |                                |
|                              | Total         | 77     | 41    | 12     | 22  | 40    | 8     | 200   | 100 (100)   |                                |

* cerebrospinal fluid.
As shown in Table 1, the 23 *A. baumannii* isolates were predominantly isolated from urine samples 16 (69.6%), sputum 5 (21.7%), and csf 2 (8.7%). Twenty-one (92.3%) *A. baumannii* isolates were collected from female patients: from urine 16 (76.2%), sputum 4 (19%), and csf 1 (4.8%). In male patients, 2 (8.7%) isolates were obtained, one isolate was collected from sputum and one from csf. The total age (of both male and female patients recorded an average of (±SD) 41.5 ± 16.23, 38.8 ± 28.40, and 28.5 ± 33.20 from urine, sputum, and csf sample origin (Table 2).

### Table 2. Distribution of *A. baumannii* isolates according to sample source.

| Variables | Sample Origin | Sign |
|-----------|---------------|------|
|           | Urine | Sputum | CSF | Total |       |
| Gender    |       |       |     |       |       |
| Male      | 0     | 1      | 1   | 1     | 2     |
| Female    | 16    | 4      | 1   | 4.8   | 21    |
| Total     | 16    | 5      | 2   | 8.7   | 23    |
| Age       |       |       |     |       |       |
| Male (mean ± SD) | 0.0   | 18.0 ± 19.02 | 52.0 ± 19.21 | 35.0 ± 13.58 | 0.049 * |
| Female (mean ± SD) | 41.5 ± 4.80 | 44.0 ± 9.60 | 5.0 ± 19.21 | 30.17 ± 7.34 |       |
| Total (mean ± SD) | 41.5 ± 16.23 | 38.8 ± 28.40 | 28.5 ± 33.20 | 39.8 ± 19.90 | 0.695 ns |
| Age groups | 0–15 years | 0 | 0.0 | 1 | 50.0 | 1 | 50.0 | 2 |
|           | 16–30 years | 7 | 87.5 | 1 | 12.5 | 0 | 0.0 | 8 |
|           | 31–55 years | 4 | 66.7 | 1 | 16.7 | 1 | 16.7 | 6 |
|           | >56 years | 5 | 71.4 | 2 | 28.6 | 0 | 0.0 | 7 |
| Total     | 16 | 69.6 | 5 | 21.7 | 2 | 8.7 | 23 |

* * significant at \( p < 0.05; \) ns, non-significant at \( p > 0.05. *

### 2.2. Antimicrobial Susceptibility Profiles of *A. baumannii*

Antimicrobial susceptibility profile was determined using 20 antibiotics, the susceptibility profiles were different in each isolate (Figure 1). The antimicrobial susceptibility profiles of *A. baumannii* were represented in Table 3, with the difference between S, R, and I assessed statistically with different antibiotics at 0.05 level. All the examined *A. baumannii* strains were resistant to a minimum of one antimicrobial agent in three or more antimicrobial categories (multidrug-resistant (MDR)), of which 19 (82.6%) were resistant to a minimum of one antimicrobial agent in all but two or less antimicrobial categories (extensively drug-resistant (XDR)) (Figure 1). As shown in Table 3, the strains, collectively, were resistant to oxacillin, nalidixic acid, and amoxicillin/clavulanic acid. The resistance rates to quinolones—ciprofloxacin, ofloxacin, levofloxacin, and norfloxacin were 69.6, 60.9, 65.2, and 69.6%, respectively. Resistance rates to aminoglycosides—tobramycin, gentamycin, and amikacin were 65.2, 73.9, and 52.2%, respectively. Cephalosporins resistance rates were 87, 91.3, and 56.5% for ceftazidime, cefotaxime, and cefepime, respectively. Carbapenem resistance showed 52.2, 47.8, 87, and 73.9% against meropenem, imipenem, ertapenem, and doripenem, respectively. The polypeptides polymyxin B and colistin were the most active antimicrobials agents against the studied *A. baumannii* with a sensitivity of 82.6% and 73.9%, respectively (Table 3).
Figure 1. Random Amplification of Polymorphic DNA (RAPD) type, strain, source, carbapenemases, antimicrobial susceptibility, and MHT test of the 23 A. baumannii isolates. Individual isolates showing hierarchical clustering of isolates and factors. Binary factor (carbapenemase genes) indicated by presence (+) and absence (-); however, ordinal factor (antibiotics) indicating resistance by orange color, intermediate (yellow), and sensitive (green). Abbreviations: tobramycin (TOB), gentamycin (CN), amikacin (AK), norfloxacin (NOR), levofloxacin (LEV), ciprofloxacin (CIP), nalidixic acid (NA), ampicillin (AMP), piperacillin (PRL), amoxicillin/clavulanic acid (ATM), ceftazidime (CAZ), cefepime (FEP), cefotaxime (CTX), meropenem (MEM), imipenem (IPM), doripenem (DO), ertapenem (ETP), colistin (CT), and polymyxin B (PB).

Table 3. Antimicrobial resistance profiles of A. baumannii.

| Antimicrobial | Resistance (n) % | Sign. |
|---------------|-----------------|-------|
|               | S       | R       | I       |
| Tobramycin    | (8) 34.8% | (15) 65.2% | 0      | 0.144 ns |
| Gentamycin    | (5) 21.7% | (17) 73.9% | (1) 4.3% | <0.001 * |
| Amikacin      | (11) 47.8% | (12) 52.2% | 0      | 0.835 ns |
| Aztreonam     | (3) 13%    | (20) 87% | 0      | <0.001 * |
| Norfloxacin   | (7) 30.4% | (16) 69.6% | 0      | 0.061 ns |
| Levofloxacin  | (6) 26.1% | (15) 65.2% | (2) 8.7% | 0.003 * |
| Ofloxacain    | (8) 34.8% | (14) 60.9% | (1) 4.3% | 0.0004 * |
2.3. Prevalence of Carbapenemase Producers

Modified Hodge Test (MHT) was carried out to detect the carbapenemases production in A. baumannii strains \((n = 23)\), the results revealed that the production rates were 56.5, 60.9, and 78.3% with meropenem, imipenem, and ertapenem disks, respectively (Figure 1). Collectively, all the tested strains were MHT positive to a minimum of one carbapenem species used in the test.

2.4. Prevalence of Carbapenemase Encoding Genes

The multiplex-PCR revealed that \(\text{bla}_{\text{OXA-23}}\)-like genes were the most predominant among the tested strains (65.2%), followed by \(\text{bla}_{\text{OXA-23}}\) (30.4%) and \(\text{bla}_{\text{OXA-58}}\) (17.4%), as described in Figures 1 and 2. Furthermore, the prevalence of NDM, VIM, and IMP genes families within the tested strains was 13, 43.5, and 60.9%, respectively (Figure 1).

2.5. Random Amplification of Polymorphic DNA (RAPD) PCR Fingerprinting

Ten RAPD primers (Table 4) were tested for all the 23 strains, five were chosen according to their reproducible and discriminating powers. The RAPD typing of the 23 community-acquired isolates...
has been performed by using all five RAPD primers (P1, P2, P3, P4, and P5) (Table 4). For each strain, five RAPD gels were combined into one single lane (Figure 3a). Each RAPD PCR generated up to 8 fragments per strain. The cumulative patterns yielded approximately 35 bands with fragments extended from 500 to 2000 bp per strain that were used for cluster analysis. Construction of the dendrogram was performed using GelJ cluster analysis software, the Dice coefficient and Unweighted Pair Group Method with Arithmetic Mean (UPGMA) method were used for analysis at ≥90 percentages similarity. In Figure 3b, RAPD discriminated 11 genetically distinct groups for the 23-community acquired A. baumannii. However, antibiotic resistance profiles were different between the isolates within the same group (Figure 1).

Figure 3. RAPD genotyping of the strains. (a) Combined RAPD patterns of 23 clinical Acinetobacter isolates obtained after electrophoresis of the PCRs with five different primers individually. For each primer, five RAPD gels were combined into one image. (b) RAPD dendrogram was constructed with GelJ cluster analysis software by Unweighted Pair Group Method with Arithmetic Mean (UPGMA). Percentages of similarity and primers used as presented in Table 3 on the top line of the dendrogram. RAPD type and strain code as in Table 3 and strain numbers as presented in Figure 3a appear on the right (between parenthesis).
3. Discussion

The rise and proliferation of antibiotic-resistant pathogenic microorganisms are of incredible worry to clinicians. Since the original depiction of a penicillin-inactivating catalyst in Escherichia coli, the furious 75-year battle against these microbes has been alluded to as an “unwinnable war” [31]. Recent clinical consideration has concentrated on the expanding rate of lactose non-fermenting, Gram-negative pathogens liable for health settings-gained infections [31]. In this gathering, Acinetobacter species are rising as pathogens that now and again cause infections in patients in intensive care units [32]. In this kind of bacteria, protection from different classes of anti-infection agents genuinely bargains with the capacity to treat patients who are tainted with these pathogens. Hence, for the immunocompromised host, current efficient therapy is a matter of survival.

In the existing study, 44 (22%) isolates were preliminarily identified as Acinetobacter spp., using differential growth morphology and biochemical tests, from 200 Gram-negative, non-fermentative strains collected between October 2017 and August 2018 with several types of infections from different private and governmental laboratories through Egypt. Twenty-nine of the 44 (65.9%) strains were identified biochemically as A. baumannii by the API 20NE system. It is widely accepted that identification of non-fermenting, Gram-negative bacilli is usually carried out by commercial identification systems such as the API 20 NE [10,11].

Acinetobacter spp. characterization to the genospecies level using phenotypic techniques is difficult, especially identifying strains belonging to A. baumannii [33]. In this work, PCR detection of A. baumannii specific OXA-51 was used to confirm the identification of A. baumannii, 23 isolates showed the presence of blaOXA-51-like genes and was confirmed by 16s–23s rRNA region sequencing. Turton et al. (2006) provide evidence that A. baumannii can be identified by the detection of blaOXA-51 by PCR [26]. However, a plasmid-mediated blaOXA-51-like carbapenemase has been found in other genomic species rather than A. baumannii, and the accuracy of using blaOXA-51 detection as a tool for differentiating A. baumannii from other Acinetobacter species has been argued [34]. The sequencing of bacterial 16S-23S rRNA intragenic spacer region has proved useful in taxonomic studies to distinguish between different species of common genus [35].

During the present work, the most prevalent Gram-negative, non-fermentative isolates were Pseudomonas aeruginosa 156 (78%) followed by A. baumannii 23 (11.5%), A. lwoffi 7 (3.5%), A. calcoaceticus 6 (3%), Burkholderia cepacia 3 (1.5%), Stenotrophomonas maltophilia 3 (1.5%), and A. nosocomialis 2 (1%). Several studies showed that the highest prevalent Gram-negative non-fermentative pathogen in hospital-acquired infections is P. aeruginosa (50–88%) followed by A. baumannii (5–35%) [36–38].

In the current work, A. baumannii was isolated from urine (69.6%), followed by sputum (21.7%) and csf (8.7%). In studies on community-acquired A. baumannii in China, Taiwan, and Australia, 63.8% of cases were pneumonia and 36.2% cases were bacteremia [39]. Falagas et al. (2007) reviewed 26 case reports regarding 43 non-hospitalized patients having A. baumannii infections; from those, 88.4% pneumonia, 4.7% meningitis, 4.3% tissue infection, 4.3% ocular infection, and 4.3% endocarditis [39]. In our results, the highest percentage of isolation was from female patients (91.3%), followed by male patients (8.7%). Contrary to our results, Rebic et al. (2018) observed that A. baumannii infection was higher in male patients (58%) than female patients (42%) in a study that included 622 in- and out-patients in a Bosnian hospital [40]. These differences may be due to the randomized sampling pattern for our collected isolates without the concentration on specific symptoms or cases. Interestingly, Pires et al. (2020) found that female mice were more susceptible to A. baumannii pneumonia [41].

This study highlighted the importance of Acinetobacter spp. as an important community-acquired pathogen in contrast to the study done by Basuda K. and Medhabi S. (2013), which was carried out in a hospital setting and found that the predominant Acinetobacter spp. were A. calcoaceticus (42%) and A. baumannii (34%), and that both developed resistance to commonly-used antibiotics [14]. Recently, an exponential elevated rate of community-acquired A. baumannii cases has been reported that led to increased awareness of the danger of this type of infection with high pathogenicity and death.
rates, especially in equatorial and sub-equatorial geographical regions [39]. However, *Acinetobacter* spp. true incidence among Gram-negative, non-fermenting pathogens circulating the community has not been reported, to the best of our knowledge. Importantly, all of *Acinetobacter* spp. identified in this work were unidentified by the collecting lab, failure, and/or misidentification of *Acinetobacter* spp. with other gram-negative bacteria is common [12,13,15].

The small size and distribution of *A. baumannii* outer membrane porins are responsible for the decreased membrane permeability and may explain their effective, de facto higher resistance to certain antimicrobials [42]. Resistance to aminoglycosides like amikacin was 52.2% within the studied strains, which is close to other studies on *A. baumannii* from Egypt with 68.5% resistance [43]. *A. baumannii* cephalosporins resistance was similar to other studies in Egypt, Saudi Arabia, and India, where it ranges from 60 to 100% [44–46].

The resistance of the strains in this work to quinolones, nalidixic acid, and ciprofloxacin was close to studies from Algeria, Egypt, and Saudi Arabia [44–46]. *A. baumannii* strains’ resistance to carbapenems like meropenem and imipenem (65.2 and 56.5%, respectively) were comparable to other studies in Egypt (57.5 and 65%) and Saudi Arabia (50 and 48.1%) [44,45]. The incidence of carbapenem resistance is becoming a serious problem in *A. baumannii* worldwide. A plethora of reports on carbapenem resistant *A. baumannii* exists, which have been associated with carbapenemases production [47–49].

In this work, carbapenemases production, as measured by MHT, demonstrated that 56.9, 60.9, and 78.3% of the strains produce carbapenemase inhibiting either meropenem, imipenem, or ertapenem, respectively. Therefore, all *Acinetobacter* isolates were phenotypically positive carbapenem producers for at least one type of carbapenem disk in the MHT test. In another study from Egypt, 60% of *A. baumannii* were positive for carbapenemases production by MHT assay using meropenem disks [49]. Recently, the accuracy of MHT was urged, suggesting that carbapenem resistance of an isolate is more likely correlated to the type of carbapenem produced rather than the level of production [50–52].

The persistence of OXA-51 gene family are found in all tested *A. baumannii* strains and believed to be intrinsic to this genomic species, but recently this was detected in another species perhaps due to horizontal gene transfer [25,26]. *A. baumannii* can easily develop resistance to a new lactam ring containing antibiotics due to the presence of this variety of OXA enzymes. In the current study, among the 23 carbapenem-resistant strains, 30.4% strains were detected as positive for the presence of blaOXA-23-like genes, 65.2% for blaOXA-24-like genes, and 17.4% for blaOXA-58-like genes. This differed from the previously reported prevalence of OXA type carbapenemases in 40 carbapenem-insensitive *A. baumannii* isolates from hospitalized patients collected from Egypt in 2014, which were 50, 7.5, and 5%, respectively [45]. This difference in OXA carbapenemases prevalence may indicate different genetic lineage between community-acquired and hospital-acquired *A. baumannii* in Egypt [45]. In Taiwan, the prevalence of blaOXA-23-, blaOXA24-, and blaOXA-58-like genes was 28.69, 90.91, and 0%, respectively [53]. The prevalence of other types of carbapenemases, such as blaNDM, blaVIM, blaIMP was similar to other studies in Egypt, where it was found that the incidence of blaNDM was 39.3%, blaIMP 95.7%, and blaVIM 93% [54–56].

All profiles recognized in this investigation were ordered into 11 groups that were seen in 23 strains by utilizing RAPD-PCR demonstrating high genotypic varieties. Various examinations have been coordinated on genotyping *A. baumannii* strain by different genotyping techniques, and various genetic profiles have been represented in various regions. The findings of this study are similar to that of studies reported by Asadian et al. (2019), who were also able to cluster *A. baumannii* strains based on their genetic relatedness using RAPD-PCR [57]. The assorted variety of genetic patterns among the isolates is probably due to a wide assortment of sampling locations, otherwise several strains with identical genetic pattern and common origin would have been observed. It is also noticeable that strains originated from different infection sites were grouped genetically in the same cluster, suggesting the same origin and increase of the danger of multiple infection capabilities for such genotypes. Distinguishing proof of a satisfactory degree of decent genetic variety among the strains
by this strategy utilizing five consolidated RAPD oligos demonstrates that this technique is valuable for examining and typing *A. baumannii*, and strains with various roots can be arranged into various clusters. This agreed with Koeleman et al. (1998), who proposed using at least 5 RAPD primers to better discriminate genetic diversity between bacterial isolates [58].

4. Materials and Methods

4.1. Ethical Approval

The research was ethically approved by the Faculty of Science—Suez Canal University (2017 MS518) and is in compliance with the Helsinki Declaration of 1964 and the resulting revisions or comparative moral guidelines. This research was waived from written informed consent/assent/parental permission, and the patients were informed orally.

4.2. Study Design and Bacterial Isolates

A sum of 200 non-repetitive, Gram-negative, non-fermentative isolates was selected from 2108 isolates from non-hospitalized (for the last 12 months) symptomatic patients from private medical and microbiological analysis laboratories across Egypt during a period of 11 months from September 2017 to August 2018. These bacteria were originally isolated from sputum, urine, blood, cerebrospinal fluid. Isolates (*n* = 200) were streaked on MacConkey agar (OXOID, Basingstoke, England), Lead Acinetobacter agar (Hardy Diagnostics, Santa Maria, CA, USA), and CHROMagar (Oxoid, Basingstoke, England), and incubated under aerobic conditions at 37 °C for 48 hours. Gram staining, motility, oxidase, peroxidase, and oxidative-fermentation reactions were performed according to standard techniques [59]. API 20NE bacterial identification system (Biomerieux, Marcy-l’Étoile, France) was used for species identification.

4.3. Molecular Identification of *A. baumannii*

*A. baumannii* strains, identified by API 20NE system, were confirmed by PCR detection of *bla*OXA-51-like genes, according to Evans et al. (2008) [60] and ribosomal RNA 16S–23S sequencing, based on the method of Chang et al. (2005) [33].

4.4. Antimicrobial Susceptibility Testing of *A. baumannii*

The sensitivity of *Acinetobacter* isolates to different families of antibiotics were inclusive of: aminoglycosides—tobramycin (10 µg), amikacin (30 µg), and gentamicin (10 µg); beta-lactam combinations—piperacillin/tazobactam (100/10 µg) and amoxicillin/clavulanic acid (20/10 µg); quinolones—norfloxacin (10 µg), levofloxacin (5 µg), Ofloxacin (5 µg), nalidixic acid (30 µg), and ciprofloxacin (5 µg); monobactams—aztreonam (30 µg); cephalosporins—cefeplime (30 µg), ceftazidime (30 µg), cefotaxime (30 µg); carbapenems—doripenem (10 µg), ertapenem (10 µg), imipenem (10 µg), meropenem (10 µg), and Polypeptides—polymyxin B (300 U) and colistin (10 µg) were examined by Kirby–Bauer disk diffusion approach [61]. *Escherichia coli* ATCC 25922 was used in quality control. Antibiotic discs were obtained from Oxoid, UK. Colistin and polymyxin resistance was confirmed by MIC assay [61].

4.5. Screening of Carbapenemases Production

Screening carbapenemases production was performed using ertapenem, imipenem, and meropenem (10 µg) discs by the Modified Hodge Test (MHT) in consonance with Shivaprasad et al. (2014) [62]. *Acinetobacter baumannii* NCTC 13301 and *Escherichia coli* ATCC 8739 were used as positive and negative controls, respectively.
4.6. Molecular Detection of Carbapenemase Encoding Genes

Purified bacterial colonies were resuspended in sterile saline (200 µL). Genomic DNA was obtained by the bacterial-genomic DNA extraction kit (BioVision, New Minas, NS, Canada) following manufacturer directions. PCR was used to detect \textit{blaOXA-51} gene in the isolates as described previously [60]. Multiplex PCR was used for the detection of \textit{blaOXA-23}, \textit{blaOXA-24}, \textit{blaOXA-51}, and \textit{blaOXA-58} genes as previously described with slight modification [63]. Different \textit{blaOXA-23} primers used in the multiplex PCR for better discrimination [64]. PCR visualization of \textit{blaIMP}, \textit{blaVIM}, \textit{blaNDM}, \textit{blaGES}, and \textit{blaKPC} was performed as described previously [63,65]. Primers and fragments’ lengths are presented in Table 3. \textit{blaOXA-58} and \textit{blaOXA-24} amplicons were confirmed by direct PCR sequencing.

4.7. RAPD—Genotyping of A. baumannii

Ten decanucleotide primers obtained from RAPD kit (Eurofins Biodiagnostics) and used in this study (Table 3). RAPD analysis was accomplished in accordance with Zhang et al. (2008) [66]. For cluster analysis, a DNA fingerprint java application analysis software (Gel) was used (downloaded from https://sourceforge.net/projects/gelj/) [67]. UPGMA method was applied in cluster algorithm and dendrogram creation using Dice as a similarity index. A similarity index of \( \geq 90\% \) was used for clustering genetically-related isolates.

4.8. Statistical Analysis

Data were checked for normality using Shapiro–Wilk normality testing at \( p < 0.05 \). Parametric data were presented as mean followed by standard deviation. Non-parametric data were presented as number and percentages. Differences in parametric data were checked using one-way analysis of variance (ANOVA) at \( p < 0.05 \). Non-parametric data were checked using Chi squared, and Kruskal–Wallis test statistic to differentiate between (sensitive, intermediate, resistant). Dendrogram were plotted by hierarchical clustering analysis of isolates and factors, both binary factor (carbapenemase genes) and ordinal factor (antibiotics) using Ward’s method and squared Euclidean distances. Statistical analyses were carried by IBM SPSS version 23.0 for Mac OS. (Table 4).

### Table 4. Sequence, amplicon size and annealing temperature of oligos used in the study.

| Oligo | Sequence (5’→3’) | Amplicon Size (bp) | Annealing Tmp (°C) | Reference |
|-------|------------------|-------------------|-------------------|-----------|
| (16-23S ITS) P-1512F | GTCGTAAACAAGTGACCGA | 607 | 60 | [33] |
| (16-23S ITS) P-6R | GGGTTCC/TCCCCC/ATGC | | | |
| \textit{blaOXA-69F} (F) | CTAAATGGATGATCAAG | 975 | 48 | [60] |
| \textit{blaOXA-69R} (R) | CCAGTGGATGGATGGATAGAT | | | |
| \textit{blaOXA-51F} (F) | AGATTTTCTGATGATGGA | 353 | | [63] |
| \textit{blaOXA-51R} (R) | TGGATGGATGATGATGGA | | | |
| \textit{blaOXA-23F} (F) | GATGTGTCATAGTATTGGTCT | 1058 | 52 | [64] |
| \textit{blaOXA-23R} (R) | TCACAAACACTGAGC | | | |
| \textit{blaOXA-24F} (F) | GTTGAAGGCAAAAGCG | 246 | | [63] |
| \textit{blaOXA-24R} (R) | AGTGGACGCAAAGCG | | | |
| \textit{blaOXA-58F} (F) | AAGTAGTGACCGCCCCTTA | 599 | | [63] |
| \textit{blaOXA-58R} (R) | CCCCTTGCGGCTCACAT | | | |
Table 4. Cont.

| Oligo     | Sequence (5′→3′)                                      | Amplicon Size (bp) | Annealing Tmp (°C) | Reference |
|-----------|------------------------------------------------------|--------------------|-------------------|-----------|
| (blaIMP) IMP-F | GGAATAGAGTGGCTAAYTCTC GATGGTGTTTGGTGGATTAGC     | 232                |                   |           |
| (blaIMP) IMP-R | GTTTAAAYAAAACAAACCC GAAATGGCAGGACACCA   |                    |                   |           |
| (blaVIM) VIM-F | GATGGTGTTTGGTGGATTAGC GGAATGGCAGGACACCA | 390                |                   |           |
| (blaVIM) VIM-R | GTTTAAAYAAAACAAACCC GAAATGGCAGGACACCA |                    |                   |           |
| (blaNDM) NDM-F | GGTITGGGCATCTGGITTTAC CGGAATGGCAGGACACCA | 621                | 52                | [63]      |
| (blaNDM) NDM-R | GTTTAAAYAAAACAAACCC GAAATGGCAGGACACCA |                    |                   |           |
| (blaKPC) KPC-F  | CGTCTAGTTCTGCTGTCTTGG CTTGTGATCCCTTGGTGGGGGC | 798                |                   |           |
| (blaKPC) KPC-R  | CGTCTAGTTCTGCTGTCTTGG CTTGTGATCCCTTGGTGGGGGC |                    |                   |           |
| (blaGES) GES-F | ATGGCGCTTCATCCAGCGACA CTATTTGTCCGCTCAGGAG | 863                | 55                | [65]      |
| (blaGES) GES-R  | ATGGCGCTTCATCCAGCGACA CTATTTGTCCGCTCAGGAG |                    |                   |           |
| OPM-01 (P1)     | GTTGTTGGCT                                       |                    |                   |           |
| OPM-07 (P2)     | CCGTGACTCA                                        |                    |                   |           |
| OPM-09 (P3)     | GTCTTGCGGA                                        |                    |                   |           |
| OPQ-06 (P4)     | GAGGGCCCTTG                                       |                    |                   |           |
| OPQ-08 (P5)     | CTCCAGCGGA                                        |                    |                   |           |
| OPQ-03 (P6)     | GGGGGATGAG                                        |                    |                   |           |
| OPQ-02 (P7)     | TCTGTGCTGCT                                       | Variable           | 40                | Eurofins Kit |
| OPQ-05 (P8)     | GGGAACGTGT                                        |                    |                   |           |
| OPQ-04 (P9)     | AGTGCGCTGA                                        |                    |                   |           |
| OPQ-10 (P10)    | TGTGCCGCGAA                                       |                    |                   |           |

5. Conclusions

In this work, we identified multidrug-resistant strains of *A. baumannii* from community-acquired infections in Egypt. The isolated *A. baumannii* strains exhibited multidrug resistance with the production of carbapenemases. The *blaOXA-24* genes were the most predominant among the tested strains, followed by *blaOXA-23* and *blaOXA-58*. In addition, the examined strains harbored IMP, VIM, and NDM genes. Genetic relatedness studies revealed 11 different genotypes with more than 90% similarity. The current study provided phenotypic and genotypic characterization data of community-acquired *A. baumannii*. Further studies are needed to assess other resistance genes, the potential virulence factors of these community-acquired strains, and the severity of the clinical outcome associated with these strains.

The findings of this research essentially encourage continual precise monitoring and reporting of the incidences and antimicrobial susceptibility of community-associated *Acinetobacter* spp. to help clinicians in the containment of these life-threatening infections.

**Author Contributions:** Conceptualization, W.E.-K. and L.M.; methodology, A.E.-T. and H.F.H.; software, R.Y., H.F.H.; validation, L.M., R.Y., and H.F.H., and N.A.-H.; formal analysis, N.A.-H.; investigation, A.E.-T., H.F.H., and W.E.-K.; resources, N.A.-H.; data curation, A.E.-T.; writing—original draft preparation, W.E.-K.; writing—review and editing, L.M., H.F.H., and R.Y.; visualization, R.Y.; supervision, W.E.-K.; project administration, W.E.-K., H.F.H., and L.M.; supervision, R.Y., A.E.-T., and N.A.-H. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Conflicts of Interest:** The authors declare no conflict of interest.
References

1. World Health Organization. WHO Publishes List of Bacteria for Which New Antibiotics Are Urgently Needed. Available online: https://www.who.int/en/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed (accessed on 20 August 2019).

2. Peleg, A.Y.; de Breij, A.; Adams, M.D.; Cerqueira, G.M.; Mocari, S.; Galardini, M.; Nibbering, P.H.; Earl, A.M.; Ward, D.V.; Paterson, D.L.; et al. The success of acinetobacter species; genetic, metabolic and virulence attributes. PLoS ONE 2012, 7, e46984. [CrossRef] [PubMed]

3. Joly-Guillou, M.L. Clinical impact and pathogenicity of acinetobacter. Clin. Microbiol. Infect. 2005, 11, 868–873. [CrossRef] [PubMed]

4. Porter, K.A.; Rhodes, J.; Dejsirilert, S.; Henchaichon, S.; Siludjai, D.; Thamthitiwat, S.; Prapasiri, P.; Jorakate, P.; Kaewpan, A.; Peruski, I.F.; et al. Acinetobacter bacteraemia in Thailand: Evidence for infections outside the hospital setting. Epidemiol. Infect. 2014, 142, 1317–1327. [CrossRef] [PubMed]

5. Dexter, C.; Murray, G.L.; Paulsen, I.T.; Peleg, A.Y. Community-acquired acinetobacter baumannii: Clinical characteristics, epidemiology and pathogenesis. Expert Rev. Anti-Infect. Ther. 2015, 13, 567–573. [CrossRef] [PubMed]

6. De Vos, D.; Pirnay, J.-P.; Bilocq, F.; Jennes, S.; Verbeeken, G.; Rose, T.; Keersebilck, E.; Bosmans, P.; Pieters, T.; Hing, M.; et al. Molecular epidemiology and clinical impact of acinetobacter calcoaceticus-baumannii complex in a Belgian burn wound center. PloS ONE 2016, 11, e0156237. [CrossRef] [PubMed]

7. Son, Y.W.; Jung, I.Y.; Ahn, M.Y.; Jeon, Y.D.; Ann, H.W.; Ahn, J.Y.; Ku, N.S.; Han, S.H.; Choi, J.Y.; Song, Y.G.; et al. A case of community-acquired pneumonia caused by multidrug-resistant acinetobacter baumannii in Korea. Infect. Chemother. 2017, 49, 297–300. [CrossRef]

8. Peng, C.; Zong, Z.; Fan, H. Acinetobacter baumannii isolates associated with community-acquired pneumonia in West China. Clin. Microbiol. Infect. 2012, 18, E491–E493. [CrossRef]

9. Ong, C.W.; Lye, D.C.; Khoo, K.L.; Chua, G.S.; Yeoh, S.F.; Leo, Y.S.; Tambyah, P.A.; Chua, A.C. Severe community-acquired acinetobacter baumannii pneumonia: An emerging highly lethal infectious disease in the Asia-Pacific. Respiriology 2009, 14, 1200–1205. [CrossRef]

10. Funke, G.; Funke-Kissling, P. Evaluation of the new VITEK 2 card for identification of clinically relevant gram-negative rods. J. Clin. Microbiol. 2004, 42, 4067–4071. [CrossRef]

11. Kiska, D.L.; Kerr, A.; Jones, M.C.; Caracchio, J.A.; Eskridge, B.; Jordan, M.; Miller, S.; Hughes, D.; King, N.; Gilligan, P.H. Accuracy of four commercial systems for identification of burkholderia cepacia and other gram-negative nonfermenting bacilli recovered from patients with cystic fibrosis. J. Clin. Microbiol. 1996, 34, 886–891. [CrossRef]

12. Kim, S.; Kim, M.H.; Lee, W.J.; Kang, S.Y.; Jeon, Y. Misidentification of acinetobacter baumannii as alcaligenes faecalis by VITEK 2 system; Case report. Lab. Med. 2017, 49, e14–e17. [CrossRef] [PubMed]

13. Greer, R.C.; Wangrangsimakul, T.; Amornchai, P.; Wuthiekanun, V.; Laongnualpanich, A.; Dance, D.A.B.; Limmathurotsakul, D. Misidentification of bakeraeria pseudomallei as acinetobacter species in northern Thailand. Trans. R. Soc. Trop. Med. Hyg. 2019, 113, 48–51. [CrossRef]

14. Shrestha, M.; Khanal, B. Acinetobacter species: Phenotypic characterization and antimicrobial resistance. J. Nobel Med. Coll. 2013, 2, 43–48. [CrossRef]

15. Savini, V.; Catavitello, C.; Talia, M.; Febo, F.; Balbinot, A.; Pompilio, A.; Di Bonaventura, G.; Piccolomini, R.; D’Antonio, D. Misidentification of ampicillin-sulbactam heteroresistance in acinetobacter baumannii strains from ICU patients. J. Infect. 2009, 58, 316–317. [CrossRef] [PubMed]

16. Nies, D.; Hu, Y.; Chen, Z.; Li, M.; Hou, Z.; Luo, X.; Mao, X.; Xue, X. Outer membrane protein A (OmpA) as a potential therapeutic target for Acinetobacter baumannii infection. J. Biomed. Sci. 2020, 27, 26. [CrossRef]

17. Fitzgerald, D.M. The road to resistance. Elife 2019, 8, e52092. [CrossRef]

18. Domingues, S.; Rosario, N.; Candido, A.; Neto, D.; Nielsen, K.M.; Da Silva, G.J. Competence for natural transformation is common among clinical strains of resistant acinetobacter spp. Microorganisms 2019, 7, 30. [CrossRef] [PubMed]

19. Hu, Y.; He, L.; Tao, X.; Meng, F.; Zhang, J. High DNA uptake capacity of international clone II acinetobacter baumannii detected by a novel planktonic natural transformation assay. Front. Microbiol. 2019, 10, 2165. [CrossRef] [PubMed]
20. Livermore, D.M. The impact of carbapenemases on antimicrobial development and therapy. Curr. Opin. Investig. Drugs 2002, 3, 218–224.
21. Poirel, L.; Nordmann, P. Acquired carbapenem-hydrolyzing beta-lactamases and their genetic support. Curr. Pharm. Biotechnol. 2002, 3, 117–127. [CrossRef]
22. Codjoe, F.S.; Donkor, E.S. Carbapenem resistance: A review. Med. Sci. 2019, 1249–1260. [CrossRef] [PubMed]
23. Tooke, C.L.; Hinchliffe, P.; Bragginton, E.C.; Colenso, C.K.; Hirvonen, V.H.A.; Takebayashi, Y.; Spencer, J. β-Lactamases and β-Lactamase inhibitors in the 21st century. J. Mol. Biol. 2019, 431, 3472–3500. [CrossRef]
24. Walther-Rasmussen, J.; Holby, N. OXA-type carbapenemases. J. Antimicrob. Chemother. 2006, 57, 373–383. [CrossRef]
25. Aly, M.; Tayeb, H.T.; Al Johani, S.M.; Alyamani, E.J.; Aldughaishem, F.; Alabdulkarim, I.; Balkhy, H.H. Genetic diversity of OXA-51-like genes among multidrug-resistant acinetobacter baumannii in Riyadh, Saudi Arabia. Eur. J. Clin. Microbiol. Infect. Dis. 2014, 33, 1223–1228. [CrossRef] [PubMed]
26. Turton, J.F.; Woodford, N.; Glover, J.; Yarde, S.; Kaufmann, M.E.; Pitt, T.L. Identification of acinetobacter baumannii by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. J. Clin. Microbiol. 2006, 44, 2974–2976. [CrossRef]
27. Asif, M.; Alvi, I.A.; Rehman, S.U. Insight into acinetobacter baumannii: Pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infect. Drug Resist. 2018, 11, 1249–1260. [CrossRef]
28. Zarrilli, R.; Giannouli, M.; Tomasone, F.; Triassi, M.; Tsakris, A. Carbapenem resistance in acinetobacter baumannii: The molecular epidemiologic features of an emerging problem in health care facilities. J. Infect. Dev. Ctries. 2009, 3, 333–341. [CrossRef]
29. Perez, F.; Hujer, A.M.; Hujer, K.M.; Decker, B.K.; Rather, P.N.; Bonomo, R.A. Global challenge of multidrug-resistant acinetobacter baumannii. Antimicrob. Agents Chemother. 2007, 51, 3471–3484. [CrossRef] [PubMed]
30. Cillóniz, C.; Dominedò, C.; Torres, A. Multidrug resistant gram-negative bacteria in community-acquired pneumonia. Crit. Care 2019, 23, 79. [CrossRef]
31. Robert, G.; Edwards, J.R. Overview of nosocomial infections caused by gram-negative bacilli. Clin. Infect. Dis. 2005, 41, 848–854.
32. Jung, S.Y.; Lee, S.H.; Lee, S.Y.; Yang, S.; Noh, H.; Chung, E.K.; Lee, J.I. Antimicrobials for the treatment of drug-resistant acinetobacter baumannii pneumonia in critically ill patients: A systematic review and Bayesian network meta-analysis. Crit. Care 2017, 21, 319. [CrossRef] [PubMed]
33. Chang, H.C.; Wei, Y.F.; Dijkshoorn, L.; Vanechouette, M.; Tang, C.T.; Chang, T.C. Species-level identification of isolates of the acinetobacter calcoaceticus-acinetobacter baumannii complex by sequence analysis of the 16S-23S rRNA gene spacer region. J. Clin. Microbiol. 2005, 43, 1632–1639. [CrossRef]
34. Lee, Y.T.; Kuo, S.C.; Chiang, M.C.; Yang, S.P.; Chen, C.P.; Chen, T.L.; Fung, C.P. Emergence of carbapenem-resistant non-baumannii species of acinetobacter harboring a blaOXA-51-like gene that is intrinsic to A. baumannii. Antimicrob. Agents Chemother. 2012, 56, 1124–1127. [CrossRef] [PubMed]
35. Maslunka, C.; Gifford, B.; Tucci, J.; Gurtler, V.; Seviour, R.J. Insertions or deletions (Indels) in the rrn 16S-23S rRNA gene internal transcribed spacer region (ITS) compromise the typing and identification of strains within the acinetobacter calcoaceticus-baumannii (Acb) complex and closely related members. PLoS ONE 2014, 9, e105390. [CrossRef]
36. Benachinmardi, K.; Padmavathy, M.; Malini, J.; Navenneeth, B. Prevalence of non-fermenting gram-negative bacilli and their in vitro susceptibility pattern at a tertiary care teaching hospital. J. Sci. Soc. 2014, 41, 162. [CrossRef]
37. Grewal, U.; Bakshi, R.; Walia, G.; Shah, P. Antibiotic susceptibility profiles of non-fermenting gram-negative bacilli at a tertiary care hospital in Patiala, India. Niger. Postgrad. Med. J. 2017, 24, 121. [CrossRef] [PubMed]
38. Sarkar, M.; Jena, J.; Pattanaik, D.; Mallick, B. Prevalence of nonfermentative gram-negative bacilli and their antimicrobial susceptibility profiles in a tertiary care hospital of Eastern India. Int. J. Adv. Med. 2018, 5, 366. [CrossRef]
39. Falagas, M.E.; Karveli, E.A.; Kelesidis, I.; Kelesidis, T. Community-acquired acinetobacter infections. Eur. J. Clin. Microbiol. Infect. Dis. 2007, 26, 857–868. [CrossRef] [PubMed]
40. Rebic, V.; Masic, N.; Teskeredzic, S.; Aljicevic, M.; Abdulzaimovic, A.; Rebic, D. The importance of acinetobacter species in the hospital environment. Med. Arch. 2018, 72, 330. [CrossRef] [PubMed]
41. Pires, S.; Peignier, A.; Seto, J.; Smyth, D.S.; Parker, D. Biological sex influences susceptibility to acinetobacter baumannii pneumonia in mice. *JCI Insight* **2020**, *5*, e132223. [CrossRef]

42. Harding, C.M.; Hennon, S.W.; Feldman, M.F. Uncovering the mechanisms of acinetobacter baumannii virulence. *Nat. Rev. Microbiol.* **2018**, *16*, 91–102. [CrossRef] [PubMed]

43. Moustafa, N.T.; El-gendy, A.O.; Saafan, A.E.; Tawakkol, W.M. Phenotypic detection of efflux mechanism in panaminoglycoside resistant acinetobacter baumannii from Egyptian clinical isolates. *Jundishapur J. Microbiol.* **2018**, *11*, [CrossRef]

44. Abdalhamid, B.; Hassan, H.; Itbaileh, A.; Shorman, M. Characterization of carbapenem-resistant acinetobacter baumannii clinical isolates in a tertiary care hospital in Saudi Arabia. *New Microbiol.* **2014**, *37*, 65–73. [PubMed]

45. Al-Agamy, M.H.; Khalaf, N.G.; Tawfick, M.M.; Shibl, A.M.; El Kholy, A. Molecular characterization of carbapenem-insensitive acinetobacter baumannii in Egypt. *Int. J. Infect. Dis.* **2014**, *22*, 49–54. [CrossRef]

46. Rynga, D.; Shariff, M.; Deb, M. Phenotypic and molecular characterization of clinical isolates of acinetobacter baumannii isolated from Delhi, India. *Ann. Clin. Microbiol. Antimicrob.* **2015**, *14*, 40. [CrossRef] [PubMed]

47. Bakour, S.; Touati, A.; Sahli, F.; Ameur, A.A.; Haouchine, D.; Rolain, J.M. Antibiotic resistance determinants of multidrug-resistant acinetobacter baumannii clinical isolates in Algeria. *Diagn. Microbiol. Infect. Dis.* **2013**, *76*, 529–531. [CrossRef]

48. Amudhan, S.M.; Sekar, U.; Arunagiri, K.; Sekar, B. OXA beta-lactamase-mediated carbapenem resistance in acinetobacter baumannii. *Indian J. Med. Microbiol.* **2011**, *29*, 269–274.

49. Al-Zahrani, I.A. Routine detection of carbapenem-resistant gram-negative bacilli in clinical laboratories. A review of current challenge. *Saudi Med. J.* **2018**, *39*, 861–872. [CrossRef]

50. June, C.M.; Vallier, B.C.; Bonomo, R.A.; Leonard, D.A.; Powers, R.A. Structural origins of oxacillinase specificity in class D beta-lactamases. *Antimicrob. Agents Chemother.* **2014**, *58*, 333–341. [CrossRef]

51. Lutgring, J.D.; Limbago, B.M. The problem of carbapenemase-producing-carbapenem-resistant- enterobacteriaceae detection. *J. Clin. Microbiol.* **2016**, *54*, 529–534. [CrossRef]

52. Wang, J.T.; McDonald, L.C.; Chang, S.C.; Ho, M. Community-acquired acinetobacter baumannii bacteremia in adult patients in Taiwan. *J. Clin. Microbiol.* **2002**, *40*, 1526–1529. [CrossRef] [PubMed]

53. Ying, C.; Li, Y.; Wang, Y.; Zheng, B.; Yang, C. Investigation of the molecular epidemiology of acinetobacter baumannii isolated from patients and environmental contamination. *J. Antibi.**2015**, *68*, 562–567. [CrossRef] [PubMed]

54. El-Sayed-Ahmed, M.A.E.-G.; Amin, M.A.; Tawakol, W.M.; Loucif, L.; Bakour, S.; Rolain, J.-M. High prevalence of bla(NDM-1) carbapenemase-encoding gene and 16S rRNA armA methyltransferase gene among acinetobacter baumannii clinical isolates in Egypt. *Antimicrob. Agents Chemother.* **2015**, *59*, 3602–3605. [CrossRef] [PubMed]

55. Alkasaby, N.M.; El Said Zaki, M. Molecular study of acinetobacter baumannii isolates for metallo-β-lactamas and extended-spectrum-β-lactamases genes in intensive care unit, Mansoura University Hospital, Egypt. *Int. J. Microbiol.* **2017**, *2017*, 3925868. [CrossRef]

56. Al-Hassan, L.; Zafer, M.M.; El-Mahallawy, H. Multiple sequence types responsible for healthcare-associated acinetobacter baumannii dissemination in a single centre in Egypt. *BMC Infect. Dis.* **2019**, *19*, 829. [CrossRef]

57. Asadian, M.; Azimi, L.; Alinejad, F.; Ostadi, Y.; Lari, A. Molecular characterization of acinetobacter baumannii isolated from ventilator-associated pneumonia and burn wound colonization by random amplified polymorphic DNA polymerase chain reaction and the relationship between antibiotic susceptibility and biofilm production. *Adv. Biomed. Res.* **2019**, *8*, 58.

58. Koeleman, J.G.; Stoof, J.; Biesmans, D.J.; Savelkoul, P.H.; Vandenbroucke-Graulx, C.M. Comparison of amplified ribosomal DNA restriction analysis, random amplified polymorphic DNA analysis, and amplified fragment length polymorphism fingerprinting for identification of acinetobacter genomic species and typing of acinetobacter baumannii. *J. Clin. Microbiol.* **1998**, *36*, 2522–2529. [CrossRef]

59. Mac Faddin, J.F. *Biochemical Tests for Identification of Medical Bacteria*, 3rd ed.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2000.

60. Evans, B.A.; Hamouda, A.; Towner, K.J.; Amyes, S.G. OXA-51-like beta-lactamases and their association with particular epidemic lineages of acinetobacter baumannii. *Clin. Microbiol. Infect.* **2008**, *14*, 268–275. [CrossRef]

61. CLSI. *Performance Standards for Antimicrobial Susceptibility Testing*; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2017.
62. Antony, B. Comparative evaluation of four phenotypic tests for detection of metallo-β-lactamase and carbapenemase production in acinetobacter baumannii. *J. Clin. Microbiol.* 2014, 8, DC05. [CrossRef]
63. Poirel, L.; Walsh, T.R.; Cuvillier, V.; Nordmann, P. Multiplex PCR for detection of acquired carbapenemase genes. *Diagn. Microbiol. Infect. Dis.* 2011, 70, 119–123. [CrossRef]
64. Jeon, B.C.; Jeong, S.H.; Bae, I.K.; Kwon, S.B.; Lee, K.; Young, D.; Lee, J.H.; Song, J.S.; Lee, S.H. Investigation of a nosocomial outbreak of imipenem-resistant acinetobacter baumannii producing the OXA-23 beta-lactamase in Korea. *J. Clin. Microbiol.* 2005, 43, 2241–2245. [CrossRef] [PubMed]
65. Çiçek, A.C.; Düzgün, A.Ö.; Saral, A.; Kayman, T.; Çüzmecl, Z.; Balci, P.Ö.; Dal, T.; Fırat, M.; Tosun, I.; Altnttop, Y.А.; et al. Detection of class 1 integron in acinetobacter baumannii isolates collected from nine hospitals in Turkey. *Asian Pac. J. Trop. Biomed.* 2013, 3, 743–747. [CrossRef]
66. Zhang, Y.; Chen, Y.; Tang, Y.; Zhang, K. Combination of ARDRA and RAPD genotyping techniques in identification of acinetobacter spp. genomic species. *Front. Biol. China* 2008, 3, 397–401. [CrossRef] [PubMed]
67. Heras, J.; Dominguez, C.; Mata, E.; Pascual, V.; Lozano, C.; Torres, C.; Zarazaga, M. GelJ—a tool for analyzing DNA fingerprint gel images. *BMC Bioinform.* 2015, 16, 270. [CrossRef] [PubMed]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).